Imugene Licences Extensive B-Cell Immuno-Oncology Portfolio
Filed with ASX · · 3 pages · English
In the deck
Earlier from Imugene
- Leslie Chong Appointed as Managing Director
- Arginine Modulator Active in Cancer Models
- Novel Anti-PD-1 Mimotope Vaccine Ready for Development
- IMU Meets Investigator for Gastric Cancer Clinical Trial
- Cancer vaccine shows early promise in clinical trial
Later from Imugene
- Imugene raises $20.1 million
- PD-1 cancer vaccine development update
- Appendix 4E and Audited Financial Report
- Imugene Completes Phase 1b Cancer Vaccine Trial Recruitment
- Imugene commences cGMP manufacture of PD-1 cancer vaccine
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene